Coloplast A/S

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coloplast A/S engages in the developing, manufacture, and markets medical products. It operates through the following segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, Advanced Wound Dressings, and Biologics. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Voice and Respiratory Care segment refers to the sale of laryngectomy and tracheostomy products. The Interventional Urology segment includes the sale of urological products, including disposable products. The Advanced Wound Dressings segment focuses on the sale of wound and skin care products. The Biologics segment represents a new segment covering the sale of tissue-based products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.

Friday, 9 February 2024 at 11.00 - 12.00 CET In connection with the publication of Coloplast's interim financial results for Q1 2023/24, to be released same day around 07.30 am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast's website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the event.

Coloplast A/S - Q1 2023/24 Earnings Release - Invitation for conference call on 9 February 2024 at 11.00am CET

Today, 7 December 2023, Coloplast A/S held its Annual General Meeting, at which EY Godkendt Revisionspartnerselskab was elected as Coloplast A/S' auditors in line with the proposal from the Board of Directors.

Coloplast A/S - Change of auditor

Articles of association for Coloplast A/S as adopted at the Annual General Meeting of Coloplast A/S held today, 7 December 2023 are enclosed. For further information, please contact Investors and analysts Anders Lonning-SkovgaardExecutive Vice President, CFOTel.

Coloplast A/S - Articles of Association

Today, 7 December 2023, Cololast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2022/23 was approved. Distribution of year-end dividend of DKK 16 per share of nominally DKK 1 was approved.

Coloplast A/S - Decisions at the Annual General Meeting 2023

The Annual General Meeting of Coloplast A/S will be held on Thursday, 7 December 2023 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark. The notice of the Annual General Meeting is enclosed.

Coloplast A/S - Notice of Annual General Meeting 2023

Coloplast A/S (OTCPK:CLPBF) Q4 2023 Earnings Conference Call November 9, 2023 5:00 AM ET Company Participants Kristian Villumsen - President and Chief Executive Officer Anders Lonning-Skovgaard - Chief Financial Officer Conference Call Participants Anchal Verma - J.P. Morgan Hassan Al-Wakeel - Barclays Maya Pataki - Kepler Cheuvreux Christian Ryom - Danske Bank Veronika Dubajova - Citi Oliver Metzger - ODDO BHF Graham Doyle - UBS Martin Parkhøi - SEB Kristian Villumsen Thank you, operator.

Coloplast A/S (CLPBF) Q4 2023 Earnings Call Transcript

Hereby please find the Annual Report 2022/23 for the group of Coloplast A/S. Attachment Annual Report 2022-23

Coloplast Finance B.V. - Announcement no.

Coloplast, a leading company within intimate healthcare, will invest around 100 million euros in a new manufacturing site in Portugal to support the company's continued growth.

Coloplast announces new manufacturing site in Portugal

Announcement of Full-year Financial Results 2022/23 (1 October 2022 - 30 September 2023) Coloplast delivered Q4 organic growth of 8% and 28% EBIT margin1). Reported revenue in DKK grew 3% to 6,226 million, impacted by unfavourable development in currencies Organic growth rates by business area: Ostomy Care 9%, Continence Care 6%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 12%), and Interventional Urology 5%.

Coloplast A/S - Full-Year Financial Results 2022/23

FY 2022/23 organic growth of 8% and 28% EBIT margin1). Reported revenue in DKK grew 9% to DKK 24,500 million Organic growth rates by business area: Ostomy Care 8%, Continence Care 7%, Voice and Respiratory Care 10% (8 months), Advanced Wound Care 7% (Advanced Wound Dressings 6%), and Interventional Urology 10%.

Coloplast A/S - Annual Report 2022/23 & Remuneration Report 2022/23

Coloplast announces financial guidance for the 2023/24 financial year. Organic revenue growth is expected around 8% and the EBIT margin is expected at 27-28%. The assumptions on the financial guidance are laid out below.

Coloplast A/S - FY 2023/24 Financial Guidance

Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind regards,Investor RelationsColoplast A/STel.

Coloplast A/S - Financial Calendar 2023-24

Monday, 4 September 2023 at 14.00 – 15.00 CEST In connection with the completion of the acquisition of Kerecis, Coloplast will host a conference call with Fertram Sigurjonsson, Founder and CEO of Kerecis.A presentation will be available on Coloplast's website before the conference call. The webcast of the conference call will be available during and after the event.

Coloplast A/S - Coloplast completes the acquisition of Kerecis - Invitation for conference call on Monday, 4 September 2023 at 14.00-15.00 CEST

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA, HONG KONG OR AUSTRALIA, EXCEPT AS PERMITTED BY APPLICABLE LAW, OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

Coloplast A/S - Announcement no. 08/2023 - Coloplast announces registration of share capital increase of 12.2 new B shares completed

Coloplast has completed the acquisition of Kerecis, announced on July 7, 2023, after receiving approval from all relevant authorities and reaching a shareholder acceptance level of 100%

Coloplast completes the acquisition of Kerecis

Coloplast A/S - Announcement no. 07/2023 – Coloplast announces completion of offering of 12.2 million new B shares

Coloplast A/S - Announcement no. 06/2023 – Coloplast launches offering to raise around DKK 9 billion through issue of new B shares in a directed issue and private placement

Coloplast A/S (OTCPK:CLPBF) Q3 2023 Earnings Call Transcript August 17, 2023 4:30 AM ET Company Participants Kristian Villumsen - President and Chief Executive Officer Anders Lonning-Skovgaard - Chief Financial Officer Conference Call Participants Maja Pataki - Kepler Cheuvreux Hassan Al-Wakeel - Barclays Christian Ryom - Danske Bank Veronika Dubajova - Citi Shubhangi Gupta - HSBC Robert Davies - Morgan Stanley Christoph Gretler - CS Samuel England - Berenberg Graham Doyle - UBS Operator Ladies and gentlemen, thank you for standing by. Welcome and thank you for joining the Coloplast Nine Months 2022/2023 Earnings Release Conference Call.

Coloplast A/S (CLPBF) Q3 2023 Earnings Call Transcript

9M 2022/23 Interim financial results, 9M 2022/23 1 October 2022 - 30 June 2023 Coloplast delivered Q3 organic growth of 8% and 28% EBIT margin1). Reported revenue in DKK grew 4% to 6,108 million Organic growth rates by business area: Ostomy Care 8%, Continence Care 9%, Voice and Respiratory Care 9%, Wound and Skin Care 4% (Wound Care 5%), and Interventional Urology 7%.

Coloplast A/S - Announcement no. 04/2023 - Interim Financial Report, 9M 2022/2023

Danish medical equipment maker Coloplast has agreed to buy Iceland-based biologic wound care firm Kerecis for up to $1.3 billion, it said on Friday.

Denmark's Coloplast buys Kerecis for up to $1.3 bln

Coloplast has signed an agreement to acquire Kerecis, an innovative, fast-growing company in the biologics wound care segment, for up to USD 1.3 billion (around DKK 8.9 billion), of which USD 1.2 billion (around DKK 8.2 billion) is an upfront cash payment

Coloplast A/S - Announcement no. 03/2023 - Coloplast announces agreement to acquire Kerecis and raises long-term growth expectations

As part of a generational change, the largest shareholder in Coloplast A/S, Niels Peter Louis-Hansen, will establish a new holding company. The company will be co-founded with Coloplast's second-largest shareholder, the Aage & Johanne Louis-Hansen Foundation. The holding company will enable the stable and long-term development of Coloplast. The joint holding company will own approximately 30% of the company capital and have approximately 52% of the votes in Coloplast.

Largest shareholder and Foundation to secure Coloplast future with new holding company

Coloplast A/S (OTCPK:CLPBF) First Half 2022-2023 Earnings Conference Call May 11, 2023 5:00 AM ET Company Participants Kristian Villumsen – President and Chief Executive Officer Anders Lonning-Skovgaard – Chief Financial Officer Conference Call Participants Hassan Al-Wakeel – Barclays Veronika Dubajova – Citi Oliver Metzger – ODDO Christian Ryom – Danske Bank Maja Pataki – Kepler Cheuvreux Lisa Clive – Bernstein Niels Granholm-Leth – Carnegie Robert Davies – Morgan Stanley Julien Ouaddour – Bank of America Operator Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the Coloplast First Half 2022-2023 Earnings Release Conference Call.

Coloplast A/S (CLPBF) First Half 2022-2023 Earnings Call Transcript

Organic growth rates by business area: Ostomy Care 6%, Continence Care 6%, Voice and Respiratory Care 9% (2 months), Wound and Skin Care 13% (Wound Care 12%), and Interventional Urology 17%.

Coloplast B.V. - Announcement no.

H1 2022/23 Interim financial results, H1 2022/23 1 October 2022 - 31 March 2023 Coloplast delivered Q2 organic growth of 8 % and 28% EBIT margin 1) . Reported revenue in DKK was up by 10%.

News for Coloplast A/S Stock (CLPBY)